Ferracci, D.; Mathis, T.; Gavoille, A.; Gerfaud-Valentin, M.; Bert, A.; Hafidi, M.; Denis, P.; Loria, O.; Kodjikian, L.; Sève, P. Long-Term Outcomes of Birdshot Chorioretinopathy Treated with Corticosteroids: A Case Reports. J. Clin. Med.2023, 12, 5288.
Ferracci, D.; Mathis, T.; Gavoille, A.; Gerfaud-Valentin, M.; Bert, A.; Hafidi, M.; Denis, P.; Loria, O.; Kodjikian, L.; Sève, P. Long-Term Outcomes of Birdshot Chorioretinopathy Treated with Corticosteroids: A Case Reports. J. Clin. Med. 2023, 12, 5288.
Ferracci, D.; Mathis, T.; Gavoille, A.; Gerfaud-Valentin, M.; Bert, A.; Hafidi, M.; Denis, P.; Loria, O.; Kodjikian, L.; Sève, P. Long-Term Outcomes of Birdshot Chorioretinopathy Treated with Corticosteroids: A Case Reports. J. Clin. Med.2023, 12, 5288.
Ferracci, D.; Mathis, T.; Gavoille, A.; Gerfaud-Valentin, M.; Bert, A.; Hafidi, M.; Denis, P.; Loria, O.; Kodjikian, L.; Sève, P. Long-Term Outcomes of Birdshot Chorioretinopathy Treated with Corticosteroids: A Case Reports. J. Clin. Med. 2023, 12, 5288.
Abstract
Purpose: To report the progression of patients diagnosed with birdshot chorioretinopathy (BSCR) initially treated with corticosteroids.
Methods: We included 39 BSCR patients followed for ≥1 year. Patients were classified into 2 groups according to their initial treatment: methylprednisolone followed by prednisone (n=28) and prednisone alone (n=11). We analyzed the progression under treatment after 1, 3, 6 months, 1 year, and at the end of follow-up.
Results: At the end of follow-up, 31/39 (79.5%) patients had reached inflammation control. Thirteen out of 28 (46.4%) and 6/11 (54.5%) patients were treated exclusively with corticosteroids, and 18/19 (94.7%) of them had reached inflammation control at the end of follow-up; their mean (range) corticosteroid dose was 3.5 (0-10) mg/day.
Conclusion: We found that the prolonged corticosteroid therapy treatment strategy resulted in inflammation control in half of BSCR patients. This control was maintained with low doses of cortisone, usually <5 mg/day.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.